Advertisement

Heart Failure pp 273-277 | Cite as

MCS: Patient Selection

  • Paul Mohacsi
  • Pascal A. Berdat
Chapter
Part of the Cardiovascular Medicine book series (CVM)

Abstract

The clinical course of chronic heart failure is usually progressive and characterized by recurrent acute decompensations, if not stabilized by evidence based medical and device therapy, as well as adaptation of life style. Patients with advanced chronic heart failure are moderately to severely symptomatic (class III and IV) and according to the ACC/AHA classification in stage C or D. Progression finally leads to the end stage heart failure (refractory symptoms as defined by ACC/AHA as stadium D). Chronic heart failure patients may also deteriorate to advanced cardiogenic shock due to an acute de novo event, such as acute myocardial infarction. Acute heart failure due to such an unexpected event or due to progression of chronic heart failure (leading to a catecholamine dependent and unstable situation) usually triggers the discussion about, whether cardiac transplantation and/or ventricular assist therapy should be considered. However, implantation of a long-term (durable) mechanical circulatory support device (i.e. left ventricular assist device, LVAD) or heart transplantation cannot be done under urgent conditions. It is of utmost importance to first stabilize the patient by using short-term (temporary) mechanical circulatory support (MCS) devices (ECMO, DeltaStream, Levitronix/CentriMag, Impella 2.5, CP or 5.0) as a so-called bridge-to-transplantation strategy.

References

  1. 1.
    Joyce E. Frailty in advanced heart failure. Heart Fail Clin. 2016;12:363–74.CrossRefGoogle Scholar
  2. 2.
    Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, Naftel DC. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36(10):1080–6.  https://doi.org/10.1016/j.healun.2017.07.005. Epub 2017 Jul 15.CrossRefPubMedGoogle Scholar
  3. 3.
    Joseph S, et al. Prospective assessment of frailty using the fried criteria in patients undergoing left ventricular assist device therapy. Am J Cardiol. 2017;120:1349–54.CrossRefGoogle Scholar
  4. 4.
    Maurer M, Horn E, Reyentovich A. Can a left ventricular assist device in individuals with advanced systolic heart failure improve or reverse frailty? J Am Geriatr Soc. 2017;65:2383–90.CrossRefGoogle Scholar
  5. 5.
    Loncar G, Springer J, Anker M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle. 2016;7:246–60.CrossRefGoogle Scholar
  6. 6.
    Flint K, et al. Frailty and the selection of patients for destination therapy left ventricular assist device. Circ Heart Fail. 2012;5:286–93.CrossRefGoogle Scholar
  7. 7.
    Flint K, Matlock D, Sundareswaran K. Pre-operative health status and outcomes after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant. 2013;32:1249–54.CrossRefGoogle Scholar
  8. 8.
    Yost G, Tatooles A, Bhat G. Preoperative nutritional assessment with the prognostic nutrition index in patients undergoing left ventricular assist device implantation. ASAIO J. 2018;64:52–5.CrossRefGoogle Scholar
  9. 9.
    Tse G, et al. Frailty and clinical outcomes in advanced heart failure patients undergoing left ventricular assist device implantation: a systematic review and meta-analysis. JAMDA. 2017;18:255–61.Google Scholar
  10. 10.
    Cooper L, et al. Assessing frailty in patients undergoing destination therapy left ventricular assist device: observations from interagency registry for mechanically assisted circulatory support. ASAIO J. 2017;64:16–23.CrossRefGoogle Scholar
  11. 11.
    Dunlay S, et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant. 2014;33:359–65.CrossRefGoogle Scholar
  12. 12.
    McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos GS, Fonseca C, Gomez Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Pedro T, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail. 2012;14:803–69.CrossRefGoogle Scholar
  13. 13.
    Jessup M, Brozena S. Heart failure (review article). N Engl J Med. 2003;348:2007–18.CrossRefGoogle Scholar
  14. 14.
    Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. N Engl J Med. 2001;345:1435–43.CrossRefGoogle Scholar
  15. 15.
    Miller LW, Rogers JG. Evolution of left ventricular assist device therapy for advanced heart failure. JAMA. 2018. Published online April 18, 2018.  https://doi.org/10.1001/jamacardio.2018.0522. CrossRefGoogle Scholar
  16. 16.
    Kirklin JK, Xie R, Cowger J, de By TMMH, Nakatani T, Schueler S, Taylor R, Lannon J, Mohacsi P, Gummert J, Goldstein D, Caliskan K, Hannan MM. Second annual report from the ISHLT Mechanically Assisted Circulatory Support Registry. J Heart Lung Transplant 2018 Jan 31. pii: S1053-2498(18)31295-6.  https://doi.org/10.1016/j.healun.2018.01.1294. [Epub ahead of print].CrossRefGoogle Scholar
  17. 17.
    De By TMMH, Mohacsi P, Gahl B, Zittermann A, Krabatsch T, Gustafsson F, Leprince P, Meyns B, Netuka I, Caliskan K, Castedo E, Musumeci F, Vincentelli A, Hetzer R, Gummert J; EUROMACS members. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. Eur J Cardiothorac Surg. 2017.  https://doi.org/10.1093/ejcts/ezx320.CrossRefGoogle Scholar
  18. 18.
    Ponikowski P, Voors, AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT (Greece), Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–200.Google Scholar
  19. 19.
    Soliman OI, Akin S, Muslem R, Boersma E, Manintveld OC, Krabatsch T, Gummert JF, de By TMMH, Bogers AJJC, Zijlstra F, Mohacsi P, Caliskan K; EUROMACS Investigators. Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score. Circulation. 2017. pii: CIRCULATIONAHA.117.030543.  https://doi.org/10.1161/CIRCULATIONAHA.117.030543.CrossRefGoogle Scholar
  20. 20.
    Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28(6):535–41.  https://doi.org/10.1016/j.healun.2009.02.015.CrossRefPubMedGoogle Scholar
  21. 21.
    Rothenburger M, Wichter T, Schmid C, Stypmann J, Tjan TD, Berendes E, Etz C, Pioux A, Löher A, Wenzelburger F, Drees G, Hoffmeier A, Breithardt G, Scheld HH. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant. 2004;23:1189–97.CrossRefGoogle Scholar
  22. 22.
    McDonagh TA, Gardner RS, Lainscak M, Nielson OW, Parissis J, Filippatos G, Anker SD. Heart Failure Association of the European society of cardiology specialist heart failure curriculum. Eur J Heart Fail. 2014;16:151–62.CrossRefGoogle Scholar
  23. 23.
    Konstam MA, Jessup M, Francis GS, Mann DL, Greenberg B. Advanced heart failure and transplant cardiology: a Subspeciality is born. J Am Coll Cardiol. 2009;53:834–6.CrossRefGoogle Scholar
  24. 24.
    Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer ? Five-year survival following first admission for heart failure. Europ J Heart Fail. 2001;3:315–22.CrossRefGoogle Scholar
  25. 25.
    NICE clinical guideline no 108: chronic heart failure (National clinical guidelines for diagnosis and management in primary and secondary care) August 2010. Royal College of physicians. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0046956/pdf/PubMedHealth_PMH0046956.pdf and Cardiology SAC Curriculum for Cardiovascular Medicine. BCS Website, 2010.
  26. 26.
    Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157–87.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Paul Mohacsi
    • 1
    • 2
    • 3
  • Pascal A. Berdat
    • 1
  1. 1.CardiovascularCenter Zürich, Hirslanden Clinics ZürichZürichSwitzerland
  2. 2.Department of Cardiac SurgeryUniversity Hospital BaselBaselSwitzerland
  3. 3.Department of Cardiovascular SurgeryUniversity Hospital BernBernSwitzerland

Personalised recommendations